630 research outputs found
Influence of social conditions during rearing on the sexual behavior, mating ability and libido of Yorkshire boars
Typescript (photocopy)
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Case report of a cervical myelomalacia caused by a thoracolumbar intradural disc herniation leading to intracranial hypotension
A 50-year-old patient was admitted with symptoms of intracranial hypotension. MRI revealed a cervical myelomalacia caused by engorged epidural veins leading to a stenosis of the spinal canal. This condition is rarely described in patients with hydrocephalus and ventricular shunts suffering from chronic overdrainage. However, the reason in this patient was a CSF leak caused by an intradural disc herniation at T12/L1. After surgery, symptoms resolved and the cervical myelomalacia and the swollen epidural veins disappeared on postoperative MRI. In patients with engorged cervical epidural veins without a ventricular shunt, a CSF leak has to be considered
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies
Cilengitide, a cyclicized arginine-glycine-aspartic acid-containing pentapeptide, potently blocks ανβ3 and ανβ5 integrin activation. Integrins are upregulated in many malignancies and mediate a wide variety of tumor-stroma interactions. Cilengitide and other integrin-targeting therapeutics have preclinical activity against many cancer subtypes including glioblastoma (GBM), the most common and deadliest CNS tumor. Cilengitide is active against orthotopic GBM xenografts and can augment radiotherapy and chemotherapy in these models. In Phase I and II GBM trials, cilengitide and the combination of cilengitide with standard temozolomide and radiation demonstrate consistent antitumor activity and a favorable safety profile. Cilengitide is currently under evaluation in a pivotal, randomized Phase III study (Cilengitide in Combination With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Phase III Randomized Clinical Trial [CENTRIC]) for newly diagnosed GBM. In addition, randomized controlled Phase II studies with cilengitide are ongoing for non-small-cell lung cancer and squamous cell carcinoma of the head and neck. Cilengitide is the first integrin inhibitor in clinical Phase III development for oncology
Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status
PURPOSE: We retrospectively evaluated the association between postoperative pre-radiotherapy tumour burden and overall survival (OS) adjusted for the prognostic value of O-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with newly diagnosed glioblastoma treated with radio-/chemotherapy with temozolomide.
MATERIALS AND METHODS: Patients were included from the CENTRIC (EORTC 26071-22072) and CORE trials if postoperative magnetic resonance imaging scans were available within a timeframe of up to 4weeks before radiotherapy, including both pre- and post-contrast T1w images and at least one T2w sequence (T2w or T2w-FLAIR). Postoperative (residual) pre-radiotherapy contrast-enhanced tumour (CET) volumes and non-enhanced T2w abnormalities (NT2A) tissue volumes were obtained by three-dimensional segmentation. Cox proportional hazard models and Kaplan Meier estimates were used to assess the association of pre-radiotherapy CET/NT2A volume with OS adjusted for known prognostic factors (age, performance status, MGMT status).
RESULTS: 408 tumour (of which 270 MGMT methylated) segmentations were included. Median OS in patients with MGMT methylated tumours was 117 weeks versus 61weeks in MGMT unmethylated tumours (p < 0.001). When stratified for MGMT methylation status, higher CET volume (HR 1.020; 95% confidence interval CI [1.013-1.027]; p < 0.001) and older age (HR 1.664; 95% CI [1.214-2.281]; p = 0.002) were significantly associated with shorter OS while NT2A volume and performance status were not.
CONCLUSION: Pre-radiotherapy CET volume was strongly associated with OS in patients receiving radio-/chemotherapy for newly diagnosed glioblastoma stratified by MGMT promoter methylation status
Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for <i>MGMT </i>promoter methylation status
韓国南部の水田における農業用殺虫剤撒布の数種蚊に対する毒性
A study carried out in rural areas of South Korea has revealed that farmer pesticide applications of fenitrothion, fenthion and certain other organophosphorus materials are highly toxic to mosquito larvae. The rates of application (0.3 to 0.9kg/ha), although not highly residual, are from 4 to 8 times higher than those required for Cu. tritaeniorhynchus control. The commonly used knapsack sprayer provides very thorough coverage on small (≤ 1ha) farmer plots. Application by power equipment and helicopters also provides excellent larval control. In comparison to previous years, the marked increase in pesticide usage may be a partial explanation for the much lower incidence of Japanese encephalitis in rural area.韓国南部の農村で行なった研究から,農民が撒布するフェニトロチオン,バイテックス及びその他の二,三の有機燐剤は蚊の幼虫に対して極めて有効であることがわかった.0.3-0.9kg/haの撒布は,残留性は大きくないけれども,コガタアカイエカの防除に必要な量の4-8倍に達する.普通に用いられている背負式噴霧機は狭い区画(1ha以下)に徹底して撒布するのに便利である.動力噴霧機やヘリコプターによる撒布もまた蚊の防除に優れた効果を示す.前年までと比較して,殺虫剤の使用量が増加したことが,農村での日本脳炎患者数の減少の1つの原因かもしれない
EGFR Gene Overexpression Retained in an Invasive Xenograft Model by Solid Orthotopic Transplantation of Human Glioblastoma Multiforme Into Nude Mice
Orthotopic xenograft animal model from human glioblastoma multiforme (GBM) cell lines often do not recapitulate an extremely important aspect of invasive growth and epidermal growth factor receptor (EGFR) gene overexpression of human GBM. We developed an orthotopic xenograft model by solid transplantation of human GBM into the brain of nude mouse. The orthotopic xenografts sharing the same histopathological features with their original human GBMs were highly invasive and retained the overexpression of EGFR gene. The murine orthotopic GBM models constitute a valuable in vivo system for preclinical studies to test novel therapies for human GBM
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
- …